Brown JP, Couillard-Despres S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG
Recent research presented at the 2024 American College of Rheumatology (ACR) Annual Meeting highlights the potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address these serious complications
+acalabrutinibGlobal APG-2449APG-2449 / FAK/ALK/ROS1 / small molecule inhibitor / OncologyALK-positive advanced or locally advanced NSCLC, treatment-naivePhase 3 registrationalOngoing
He cautioned against making comparisons across trials that didn't directly compare the drugs, where Novo's pill looks more effective and led to fewer discontinuations
10.1111/j.1742-4658.2006.05322.x 274
The impact of leucine supplementation on body composition and glucose tolerance following energy restriction: an 8-week RCT in adults at risk of the metabolic syndrome